Corcept Therapeutics Initiates Phase 2 Trial Of Relacorilant For Ovarian Cancer

(RTTNews) - Corcept Therapeutics Incorporated (CORT), Monday announced the start of BELLA, a Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab evaluating efficacy and safety in patients with platinum-resistant ovarian cancer.

BELLA is a single-arm, open-label trial with a planned enrollment of 90 women with recurrent, platinum-resistant ovarian cancer at approximately 50 sites in North America, Europe and Asia-Pacific. Patients will receive relacorilant in combination with nab-paclitaxel and bevacizumab.

"In our pivotal Phase 3 ROSELLA trial, treatment with relacorilant and nab-paclitaxel improved patients' progression-free and overall survival, without increasing their side effect burden," said Bill Guyer, PharmD, Corcept's Chief Development Officer. "BELLA will examine whether combining relacorilant with two medications - nab-paclitaxel and bevacizumab - will offer patients an additional treatment option."

Relacorilant, an oral therapy, is a selective glucocorticoid receptor (GR) antagonist that modulates cortisol activity by binding to the GR but not to the body's other hormone receptors.

Corcept is studying relacorilant in a variety of serious disorders in addition to ovarian cancer, including endogenous hypercortisolism (Cushing's syndrome) and prostate cancer.